Tim Wigle
Tim Wigle
Ribon Therapeutics
Verified email at ribontx.com
Cited by
Cited by
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
SK Knutson, TJ Wigle, NM Warholic, CJ Sneeringer, CJ Allain, CR Klaus, ...
Nature chemical biology 8 (11), 890-896, 2012
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
SK Knutson, NM Warholic, TJ Wigle, CR Klaus, CJ Allain, A Raimondi, ...
Proceedings of the National Academy of Sciences 110 (19), 7922-7927, 2013
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
M Vedadi, D Barsyte-Lovejoy, F Liu, S Rival-Gervier, A Allali-Hassani, ...
Nature chemical biology 7 (8), 566-574, 2011
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma
SK Knutson, S Kawano, Y Minoshima, NM Warholic, KC Huang, Y Xiao, ...
Molecular cancer therapeutics 13 (4), 842-854, 2014
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
E Chan-Penebre, KG Kuplast, CR Majer, PA Boriack-Sjodin, TJ Wigle, ...
Nature chemical biology 11 (6), 432, 2015
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2, 4-diamino-7-aminoalkoxy-quinazolines.
F Liu, X Chen, A Allali-Hassani, AM Quinn, TJ Wigle, GA Wasney, A Dong, ...
Journal of medicinal chemistry 53 (15), 5844-5857, 2010
A687V EZH2 is a gain-of-function mutation found in lymphoma patients
CR Majer, L Jin, MP Scott, SK Knutson, KW Kuntz, H Keilhack, JJ Smith, ...
FEBS letters 586 (19), 3448-3451, 2012
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L
A Basavapathruni, L Jin, SR Daigle, CRA Majer, CA Therkelsen, TJ Wigle, ...
Chemical biology & drug design 80 (6), 971-980, 2012
Small-molecule ligands of methyl-lysine binding proteins
JM Herold, TJ Wigle, JL Norris, R Lam, VK Korboukh, C Gao, ...
Journal of medicinal chemistry 54 (7), 2504-2511, 2011
EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity
JE Campbell, KW Kuntz, SK Knutson, NM Warholic, H Keilhack, TJ Wigle, ...
ACS medicinal chemistry letters 6 (5), 491-495, 2015
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
TJ Wigle, SK Knutson, L Jin, KW Kuntz, RM Pollock, VM Richon, ...
FEBS letters 585 (19), 3011-3014, 2011
Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins
TJ Wigle, J Martin Herold, GA Senisterra, M Vedadi, DB Kireev, ...
Journal of biomolecular screening 15 (1), 62-71, 2010
Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound
LH Mitchell, AE Drew, SA Ribich, N Rioux, KK Swinger, SL Jacques, ...
ACS medicinal chemistry letters 6 (6), 655-659, 2015
Inhibitors of RecA Activity Discovered by High-Throughput Screening: Cell-Permeable Small Molecules Attenuate the SOS Response in Escherichia coli
TJ Wigle, JZ Sexton, AV Gromova, MB Hadimani, MA Hughes, GR Smith, ...
Journal of biomolecular screening 14 (9), 1092-1101, 2009
The importance of being me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat
KW Kuntz, JE Campbell, H Keilhack, RM Pollock, SK Knutson, ...
Journal of medicinal chemistry 59 (4), 1556-1564, 2016
Directed molecular screening for RecA ATPase inhibitors
TJ Wigle, SF Singleton
Bioorganic & medicinal chemistry letters 17 (12), 3249-3253, 2007
Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas
SK Knutson, NM Warholic, LD Johnston, CR Klaus, TJ Wigle, ...
PloS one 9 (12), e111840, 2014
Novel inhibitors of E. coli RecA ATPase activity
JZ Sexton, TJ Wigle, Q He, MA Hughes, GR Smith, SF Singleton, ...
Current chemical genomics 4, 34, 2010
Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor
LH Mitchell, PA Boriack-Sjodin, S Smith, M Thomenius, N Rioux, ...
ACS medicinal chemistry letters 7 (2), 134-138, 2016
Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds
D Kireev, TJ Wigle, J Norris-Drouin, JM Herold, WP Janzen, SV Frye
Journal of medicinal chemistry 53 (21), 7625-7631, 2010
The system can't perform the operation now. Try again later.
Articles 1–20